- Investing.com
Metrics to compare | LSTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLSTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −1.8x | −0.3x | |
PEG Ratio | −0.06 | −0.05 | 0.00 | |
Price/Book | 1.8x | 1.4x | 2.6x | |
Price / LTM Sales | 115.6x | 11.5x | 3.0x | |
Upside (Analyst Target) | 88.7% | 155.4% | 55.4% | |
Fair Value Upside | Unlock | 22.6% | 8.8% | Unlock |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.